Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.» Read More
Feb 5- CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first national drugstore chain in the United States to take cigarettes off the shelves.
Feb 5- CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first national drugstore chain in the United States to take cigarettes off the shelf. "I think it will put pressure on other retailers who want to be in healthcare," said CVS Caremark Chief Medical Officer Dr.
Feb 5- CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. "I think it will put pressure on other retailers who want to be in healthcare," said CVS Caremark Chief Medical Officer Dr.
Global healthcare company Roche is confident of growth in emerging markets despite the economic slowdown.
Companies and industries that rely on low-income spenders could see a boost to the bottom line thanks to rising wages in many American states.
Michael Morrissey, Exelixis president & CEO, provides insight on clinical research of prostate cancer and its cancer drug Cometriq.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
Eli Lilly Chairman & CEO John Lechleiter provides insight on its rights to an experimental migraine drug.
Eli Lilly Chairman & CEO John Lechleiter discusses its loss of major patents, its current pipeline and when its total costs will normalize.
CNBC's Morgan Brennan reports on the FDA's four expediting pipelines. The approval rates for the drugs in these pipelines tend to be higher than those plodding the more traditional course.
But the delay in packaging the liquid version has not affected supplies of regular Tamiflu, said the Roche unit that makes the medication.
Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.
CNBC's Josh Lipton reports on the HT Growth Fund, which plans to raise $100 million over the next two years for the legal marijuana market.
CNBC's Josh Lipton reports that legal recreational pot businesses could get investment from a fund.
Colorado has issued more than 300 licenses to marijuana dispensaries. Dan Danko, High Times Magazine senior editor, discusses how Colorado is properly regulating pot distribution and explains the rigorous application process to obtain a license.
CNBC's Sara Eisen reports GlaxoSmithKline is becoming the first to stop paying doctors to promote drugs.
Muddled by inconsistent earnings and stock performances, one sector appears tougher and tougher to predict, CNBC's Jim Cramer says.
A medical marijuana dispensary in Central City, Colo.—a small gambling town nestled in the mountains near Denver—just became the first business in the United States licensed to sell marijuana to patrons without a note from their doctors.
Amazon.com is clashing with Johnson & Johnson amid complaints the online retailer hasn't stopped sales of damaged or expired products.
Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.